Although the pathophysiological role of MCU in kidney diseases remains largely unclear, a previous report has shown that an MCU inhibitor, ruthenium red, decreases proteinuria and attenuates podocyte foot process effacement in adriamycin-induced nephropathy (40). This evidence concerns the gene MCU and kidney disorder.